11,600 reports of this reaction
4.7% of all OMALIZUMAB reports
#1 most reported adverse reaction
ASTHMA is the #1 most commonly reported adverse reaction for OMALIZUMAB, manufactured by Genentech, Inc.. There are 11,600 FDA adverse event reports linking OMALIZUMAB to ASTHMA. This represents approximately 4.7% of all 248,573 adverse event reports for this drug.
OMALIZUMAB has an overall safety score of 78 out of 100. Patients taking OMALIZUMAB who experience asthma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHMA is moderately reported among OMALIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to asthma, the following adverse reactions have been reported for OMALIZUMAB:
The following drugs have also been linked to asthma in FDA adverse event reports:
ASTHMA has been reported as an adverse event in 11,600 FDA reports for OMALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHMA accounts for approximately 4.7% of all adverse event reports for OMALIZUMAB, making it one of the most commonly reported side effect.
If you experience asthma while taking OMALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.